Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 100, Issue 10, 2003, Pages 6169-6173

  Hikida, Takatoshi ^a   Kitabatake, Yasuji ^a   Pastant, Ira ^b   Nakanishi, Shigetada ^a  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; COCAINE; DONEPEZIL; GALANTAMINE; MORPHINE; NALOXONE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COCAINE DEPENDENCE; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG WITHDRAWAL; HORMONE ACTION; LOCOMOTION; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; TARGET CELL;

ACETYLCHOLINE; ANIMALS; CHOLINESTERASE INHIBITORS; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING (PSYCHOLOGY); INDANS; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; NUCLEUS ACCUMBENS; PAIN; PIPERIDINES; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 0037846457     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0631749100     Document Type: Article

References (26)

1. Pouletty, P. (2002) Nat. Rev. Drug Discovery 1, 731-736.
2. Kreek, M. J., LaForge, K. S. & Butelman, E. (2002) Nat. Rev. Drug Discovery 1, 710-726.
3. Koob, G. F., Sanna, P. P. & Bloom, F. E. (1998) Neuron 21, 467-476.
4. Nestler, E. J. (2001) Nat. Rev. Neurosci. 2, 119-128.
5. Wise, R. A. (2002) Neuron 36, 229-240.
6. Oades, R. D. & Halliday, G. M. (1987) Brain Res. Rev. 12, 117-165.
7. Pennartz, C. M. A., Groenewegen, H. J. & Lopes da Silva, F. H. (1994) Prog. Neurobiol. 42, 719-761.
8. Di Chiara, G. & Imperato, A. (1988) Proc. Natl. Acad. Sci. USA 85, 5274-5278.
9. Di Chiara, G., Morelli, M. & Consolo, S. (1994) Trends Neurosci. 17, 228-233.
10. Kawaguchi, Y., Wilson, C. J., Augood, S. J. & Emson, P. C. (1995) Trends Neurosci. 18, 527-535.
11. Tzschentke, T. M. (1998) Prog. Neurobiol. 56, 613-672.
12. Heidbreder, C. A. & Shippenberg, T. S. (1996) Synapse 24, 182-192.
13. Wang, J. Q. & McGinty, J. F. (1996) Neuroscience 75, 43-56.
14. Rasmussen, T., Sauerberg, P., Nielsen, E. B., Swedberg, M. D. B., Thomsen, C., Sheardown, M. J., Jeppesen, L., Calligaro, D. O., DeLapp, N. W., Whitesitt, C., et al. (2000) Eur. J. Pharmacol. 402, 241-246.
15. Itzhak, Y. & Martin, J. L. (2000) Psychopharmacology 152, 216-223.
16. Kaneko, S., Hikida, T., Watanabe, D., Ichinose, H., Nagatsu, T., Kreitman, R. J., Pastan, I. & Nakanishi, S. (2000) Science 289, 633-637.
17. Hikida, T., Kaneko, S., Isobe, T., Kitabatake, Y., Watanabe, D., Pastan, I. & Nakanishi, S. (2001) Proc. Natl. Acad. Sci. USA 98, 13351-13354.
18. Krall, W. J., Sramek, J. J. & Cutler, N. R. (1999) Ann. Pharmacother. 33, 441-450.
19. Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y. & Yamanishi, Y. (2002) Jpn. J. Pharmacol. 89, 7-20.
20. Isomae, K., Ishikawa, M., Ohta, M., Ogawa, Y., Hasegawa, H., Kohda, T. & Kamei, J. (2002) Jpn. J. Pharmacol. 88, 206-212.
21. Watanabe, D., Inokawa, H., Hashimoto, K., Suzuki, N., Kano, M., Shigemoto, R., Hirano, T., Toyama, K., Kaneko, S., Yokoi, M., et al. (1998) Cell 95, 17-27.
22. Yoshida, K., Watanabe, D., Ishikane, H., Tachibana, M., Pastan, I. & Nakanishi, S. (2001) Neuron 30, 771-780.
23. Bläsig, J., Herz, A., Reinhold, K. & Zieglgänsberger, S. (1973) Psychopharmacologia 33, 19-38.
24. Kieffer, B. L. (1999) Trends Pharmacol. Sci. 20, 19-26.
25. Koob, G. F. (1996) Neuron 16, 893-896.
26. Grimm, J. W., Hope, B. T., Wise, R. A. & Shaham, Y. (2001) Nature 412, 141-142.